Knight Therapeutics Inc. (GUD.TO)
| Previous Close | 5.72 |
| Open | 5.77 |
| Bid | 5.76 x 0 |
| Ask | 5.79 x 0 |
| Day's Range | 5.71 - 5.79 |
| 52 Week Range | 4.35 - 5.95 |
| Volume | |
| Avg. Volume | 75,511 |
| Market Cap | 585.774M |
| Beta (5Y Monthly) | 0.49 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Knight to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
MONTREAL, April 09, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to present a corporate update at the Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 16, 2024, at 10:30 a.m. ET at the Metro Toronto Convention Centre in Toronto. A copy of the presentation will be available at www.knighttx.com. About
- GlobeNewswire
Knight Therapeutics Inc. ranks on The Globe and Mail’s fifth-annual Women Lead Here benchmark of executive gender diversity
MONTREAL, March 28, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”) is pleased to announce it will be recognized on The Globe and Mail’s 2024 Report on Business magazine’s fifth annual Women Lead Here list. This annual editorial benchmark identifies top-level Canadian businesses with the highest executive gender diversity. The Women Lead Here benchmark was established in 2020 by Report on Business magazine and applies a proprietary research methodology to
- GlobeNewswire
Knight Therapeutics Reports Fourth Quarter and Year-End 2023 Results
Achieved Record Annual Revenues and EBITDAMONTREAL, March 21, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its fourth quarter and year ended December 31, 2023. All currency amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified. 2023 Highlights Financial results Revenues were $328,199, a
